News Briefing channel feed

Ab­b­Vie hands over $20M for Alzheimer's, Parkin­son's drugs; Au­to­lus boost­ed by a PIM

4 years ago

Sen­ate Dems call to add Medicare drug price ne­go­ti­a­tions to rec­on­cil­i­a­tion bill; Cer­tara signs $310M buy­out of soft­ware com­pa­ny

4 years ago

Celu­lar­i­ty teams up with Aus­tralian biotech to de­vel­op CAR T-cell ther­a­py; For­mer Kin­nate CEO Stephen Kaldor reels in $50M for new biotech

4 years ago

Am­gen may see $3B+ in ad­di­tion­al tax­es; EQRx, Ab­Cellera ink an­ti­body de­vel­op­ment deal

4 years ago

Roche's PD-L1 fran­chise play­er nabs pri­or­i­ty re­view; One of world's first psy­che­delics re­search in­sti­tutes opens in Aus­tralia

4 years ago

FTC pulls re­main­ing case against Ab­b­Vie; New EU clin­i­cal tri­als sys­tem com­ing in 2022; Abing­worth bets big on CymaBay

4 years ago

Top Gilead can­cer re­searcher jumps to a start­up as Dan Chen ex­its; Arde­lyx gets that CRL we've been wait­ing for

4 years ago

Roche nabs pri­or­i­ty re­view for Eylea com­peti­tor; Italy's An­geli­ni eyes CNS, rare dis­ease star­tups with $35M Lu­mi­ra fund

4 years ago

US sells Wu-Tang Clan al­bum to cov­er Shkre­li debt; Or­biMed backs GSK vet­s' Chi­nese start­up

4 years ago

Mer­ck­'s wom­en's health spin­out snags mid-stage can­di­date for preterm birth; Keytru­da nails down TNBC ap­proval af­ter March CRL

4 years ago

Bay­er poach­es newest ear­ly R&D head from Roche; Glax­o­SmithK­line earns ex­pand­ed nod for Shin­grix

4 years ago

Mod­er­na es­tab­lish­es pub­lic health-fo­cused char­i­ty; FDA ap­proves As­traZeneca di­a­betes drug for pe­di­atric use

4 years ago

Al­bireo re­veals $385K price tag for new­ly ap­proved pru­ri­tis drug; Jen­nifer Doud­na's Cari­bou up­sizes IPO

4 years ago

As­traZeneca, Alex­ion close mas­sive $39B merg­er; blue­bird bio earns EU nod for Lenti-D as big split ap­proach­es

4 years ago

Rel­ma­da to ex­plore psy­che­del­ic av­enue in pur­suit of de­pres­sion treat­ment; Ital­ian man­u­fac­tur­er joins NYSE

4 years ago

Soros, Gates back medtech's move in­to a 'so­cial en­ter­prise'; Ag­ing an­ti-re­jec­tion drug earns fresh ap­proval

4 years ago

JAK in­hibitor PDU­FA dates ex­tend­ed again as safe­ty re­view con­tin­ues; Stem­son se­cures $15M to cure hair loss

4 years ago

Eli Lil­ly part­ners with Alzheimer's cen­ter for PhI­II study; New tu­ber­cu­lo­sis con­sor­tium emerges in $218M+ project

4 years ago

Tri­al soft­ware group rais­es $45M to push de­cen­tral­ized stud­ies; $120M SPAC makes its way to Nas­daq

4 years ago

Astel­las signs on pluripo­tent stem cell part­ners at Ex­CellThera; Lit­tle Uni­cy­cive brings home $25M af­ter float­ing a small IPO

4 years ago

WHO is­sues new guide­lines for gene edit­ing; Doud­na-backed Cari­bou launch­es its first al­lo­gene­ic CAR-T tri­al

4 years ago

With TransCode go­ing pub­lic, in­dus­try sur­pass­es $10B IPO mark; Galect­in's in­hibitor shows PhIb suc­cess in can­cer treat­ment

4 years ago

Bridge­Bio adds 3 more in­sti­tu­tions to its ros­ter of col­lab­o­ra­tors; Ex­sci­en­tia lands Gates Foun­da­tion mon­ey for Covid-19 pill 

4 years ago

Ar­row­head touts Phase Ib RNAi da­ta for ccR­CC; PureTech lines up PD-1 from BeiGene for up­com­ing com­bo study

4 years ago
First page Previous page 28293031323334 Next page Last page
A service from the Financial Times